> top > docs > PMC:7377212 > spans > 22054-24855 > annotations

PMC:7377212 / 22054-24855 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T53 1815-1821 Body_part denotes Vertex http://purl.org/sig/ont/fma/fma46484

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
634 965-983 Disease denotes Infectious Disease MESH:D003141
635 1086-1119 Disease denotes Infectious Diseases Aspergillosis MESH:D003141
637 1163-1170 Disease denotes Johnson MESH:C535882
639 1916-1931 Disease denotes van de Veerdonk MESH:C536528

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T226 965-975 Disease denotes Infectious http://purl.obolibrary.org/obo/MONDO_0005550
T227 1003-1016 Disease denotes Aspergillosis http://purl.obolibrary.org/obo/MONDO_0005657
T228 1086-1096 Disease denotes Infectious http://purl.obolibrary.org/obo/MONDO_0005550
T229 1106-1119 Disease denotes Aspergillosis http://purl.obolibrary.org/obo/MONDO_0005657
T230 1325-1328 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T231 1451-1454 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T182 438-439 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T183 454-457 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T184 617-618 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T185 704-707 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T186 726-727 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T187 843-846 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T188 936-937 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T189 1171-1174 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T190 1517-1518 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T191 1526-1529 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T192 1583-1586 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T193 1760-1761 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T194 1932-1935 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T195 1992-1995 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T196 2084-2087 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T197 2162-2165 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T198 2604-2606 http://purl.obolibrary.org/obo/CLO_0008149 denotes NE
T199 2651-2653 http://purl.obolibrary.org/obo/CLO_0007860 denotes MR
T200 2748-2751 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T306 653-663 Chemical denotes antifungal http://purl.obolibrary.org/obo/CHEBI_35718
T307 1028-1033 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T308 1131-1136 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T309 2604-2606 Chemical denotes NE http://purl.obolibrary.org/obo/CHEBI_73824
T310 2651-2653 Chemical denotes MR http://purl.obolibrary.org/obo/CHEBI_74698

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T117 0-24 Sentence denotes Conflict of interest: D.
T118 25-141 Sentence denotes Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work.
T119 142-166 Sentence denotes Conflict of interest: J.
T120 167-242 Sentence denotes Youngs reports funding from the UK and Ireland Gilead Fellowship Programme.
T121 243-267 Sentence denotes Conflict of interest: T.
T122 268-415 Sentence denotes Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work.
T123 416-440 Sentence denotes Conflict of interest: A.
T124 441-538 Sentence denotes Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work.
T125 539-565 Sentence denotes Conflict of interest: D.W.
T126 566-687 Sentence denotes Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W.
T127 688-924 Sentence denotes Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W.
T128 925-1137 Sentence denotes Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group.
T129 1138-1162 Sentence denotes Conflict of interest: E.
T130 1163-1195 Sentence denotes Johnson has nothing to disclose.
T131 1196-1220 Sentence denotes Conflict of interest: V.
T132 1221-1357 Sentence denotes Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work.
T133 1358-1382 Sentence denotes Conflict of interest: T.
T134 1383-1494 Sentence denotes Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work.
T135 1495-1519 Sentence denotes Conflict of interest: B.
T136 1520-1550 Sentence denotes Patel has nothing to disclose.
T137 1551-1575 Sentence denotes Conflict of interest: J.
T138 1576-1607 Sentence denotes Rhodes has nothing to disclose.
T139 1608-1632 Sentence denotes Conflict of interest: S.
T140 1633-1737 Sentence denotes Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work.
T141 1738-1762 Sentence denotes Conflict of interest: A.
T142 1763-1888 Sentence denotes Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer.
T143 1889-1956 Sentence denotes Conflict of interest: F.L. van de Veerdonk has nothing to disclose.
T144 1957-1983 Sentence denotes Conflict of interest: P.E.
T145 1984-2243 Sentence denotes Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences.
T146 2244-2270 Sentence denotes Conflict of interest: P.L.
T147 2271-2375 Sentence denotes White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work.
T148 2376-2402 Sentence denotes Conflict of interest: M.C.
T149 2403-2509 Sentence denotes Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.
T150 2510-2528 Sentence denotes Support statement:
T151 2529-2710 Sentence denotes This work was supported by the Natural Environment Research Council (grant NE/P001165/1), Medical Research Council (grant MR/R015600/1) and Canadian Institute for Advanced Research.
T152 2711-2801 Sentence denotes Funding information for this article has been deposited with the Crossref Funder Registry.